<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922386</url>
  </required_header>
  <id_info>
    <org_study_id>LBFX05 - PERSEPOLIS</org_study_id>
    <nct_id>NCT03922386</nct_id>
  </id_info>
  <brief_title>Safety and Electrical Performances of XFINE Leads</brief_title>
  <acronym>PERSEPOLIS</acronym>
  <official_title>ProspEctive Record of Safety and Electrical Performances Of XFINE Leads: an International Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroPort CRM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicroPort CRM</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to confirm the safety and the electrical performances of the&#xD;
      XFINE passive pacing leads, for both right ventricular (RV) straight models and right atrial&#xD;
      (RA) J-shape models, up to 12 months follow-up post implant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be followed until 12 months follow-up post implant.&#xD;
&#xD;
      At each follow-up visits (3, 6 and 12 months), electrical performances will be measured and&#xD;
      safety will be monitored during the whole study duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Actual">July 23, 2021</completion_date>
  <primary_completion_date type="Actual">March 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Post market, multicenter, international, prospective, open label, two arms and longitudinal non comparative non randomized study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from XFINE lead-related complications</measure>
    <time_frame>at 6 months post implant</time_frame>
    <description>This endpoint will confirm the freedom from XFINE Lead-Related Complications (LRC) up to the 6 months post implant follow-up. The anticipated complication-free rate is 0.95, and will be compared against an a priori performance goal of 0.85.&#xD;
An XFINE Lead-Related Complication (LRC) is defined as any XFINE (RA and/or RV) lead-related Serious Adverse Device Effect (SADE) that resulted in subject death or required an additional invasive intervention (excluding re-programming) and occurred within 6 months post implant. This endpoint will be assessed independently for each lead model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrical performances confirmation</measure>
    <time_frame>at 6 months post implant</time_frame>
    <description>This endpoint will characterize the XFINE lead performances in ensuring adequate Pacing Capture Thresholds (PCT) through 6 months post implant follow-up. The values assessed in this analysis are the PCT measured at 0.50 ms (or less) pulse width at 6 months follow-up visit. The PCT measured at 6 months will be compared against an a priori performance goal of 1.0V/0.5 ms, assuming an expected pacing threshold at 6 months of 0.8V/0.5 ms with a standard deviation of 0.5V. This endpoint will be assessed independently for each lead model.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Bradycardia</condition>
  <arm_group>
    <arm_group_label>JX model</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects implanted with an RA XFINE lead (JX model)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TX model</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects implanted with an RV XFINE lead (TX model)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XFINE leads</intervention_name>
    <description>Pacemaker subjects with at least one XFINE passive lead</description>
    <arm_group_label>JX model</arm_group_label>
    <arm_group_label>TX model</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Any subject newly implanted according to the most recent guidelines from the European&#xD;
             Society of Cardiology (ESC) for less than10 days with:&#xD;
&#xD;
               -  a Single Chamber (SR) or a Dual Chamber (DR) pacemaker from Microport CRM S.r.l.&#xD;
&#xD;
               -  any right atrial and/or right ventricular XFINE lead&#xD;
&#xD;
          2. Have reviewed, signed and dated the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Included in another clinical study that could confound the results of this study such&#xD;
             as studies involving intra-cardiac device&#xD;
&#xD;
          2. Contraindication to a maximum single dose of 310 µg Dexamethasone Sodium Phosphate&#xD;
             (DSP)&#xD;
&#xD;
          3. Tricuspid valvular disease or tricuspid replacement heart valve (mechanical or tissue)&#xD;
             only for subject with DR pacemaker&#xD;
&#xD;
          4. Active myocarditis, pocket and/or lead infection&#xD;
&#xD;
          5. Age less than 18 years old or under guardianship or kept in detention&#xD;
&#xD;
          6. Life expectancy less than 1 year&#xD;
&#xD;
          7. Known pregnancy, women breastfeeding or in childbearing age without an adequate&#xD;
             contraceptive method&#xD;
&#xD;
          8. Be unavailable for the scheduled follow-up associated with this clinical study or&#xD;
             refusal to cooperate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Bardají, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Joan XXIII, Tarragona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de Cahors</name>
      <address>
        <city>Cahors</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medica - Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Nuova</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica San Carlo</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria degli Angeli</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico Casilino</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Vigevano</name>
      <address>
        <city>Vigevano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Voghera</name>
      <address>
        <city>Voghera</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Baixo Vouga, E.P.E.</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Alto Ave - Hospital da Senhora da Oliveira</name>
      <address>
        <city>Creixomil</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Leiria - Hospital de Santo André</name>
      <address>
        <city>Leiria</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Vila Nova de Gaia/Espinho</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust - Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

